PhD, Assistant Managing Director, Faculty for Medicine, University of Melbourne, USA
Editorial
Current Scenario of Covid-19 in Translational Medicine
Author(s): Gregory John Hollis*
The COVID-19 epidemic caused by the SARS-CoV-2
virus has reached pandemic proportions and caused
worldwide instability. With limited ICU beds and
insufficient respiratory support, healthcare systems
were unprepared to treat patients who progressed to a
severe acute respiratory syndrome, the dire sort of the
COVID-19 disease. Current antiviral candidates tested
or approved for COVID-19 are compounds that are
repositioned from other indications. Generally, drugs
are often repositioned for the treatment of the SARSCoV-2 infection if they need evidence of in vitro
inhibition against human coronaviruses (CoV). For
instance , remdesivir, which was originally intended for
treating Ebola, has been recently approved for the
treatment of COVID-19 requiring hospitalization; the
anti-malaria drug chloroquine is additionally being
evaluated for COVID-19 treatment; the anti-HIV drug
co.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 